MCMaud Charpentier

Maud Charpentier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maud Charpentier has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Caractérisation et contrôle de l'expression des antigènes de mélanome issus de la traduction de l'ARNm meloe

    by Maud Charpentier

    Mis en évidence par notre équipe, les antigènes de mélanome MELOE-1 et MELOE-2 présentent un profil d’expression original qui en fait des cibles de choix pour l'immunothérapie anti-cancéreuse. Ils sont en effet issus d’un lncRNA polycistronique, meloe, transcrit uniquement dans les cellules de la lignée mélanocytaire et leur traduction est restreinte aux cellules de mélanome. Cette traduction restreinte repose sur l’activation de séquences IRES exclusivement dans les cellules tumorales. Nous présentons ici l'identification d'un ORF supplémentaire de l'ARN meloe qui à la différence des deux précédents est traduit de façon strictement coiffe dépendante pour générer un polypeptide appelé MELOE-3. L’étude de son profil d’expression montre que contrairement à MELOE-1 et -2, il est exprimé non seulement dans les cellules de mélanome mais aussi dans les mélanocytes normaux. Nous documentons que MELOE-3 est très peu immunogène contrairement à MELOE-1 et 2. Cette observation est cohérente avec une tolérance immunitaire vis à vis d'une protéine exprimée physiologiquement par les mélanocytes. De plus, nos travaux sur les conditions d'activation de l’IRES de MELOE-1 dans les cellules de mélanome indiquent que des inducteurs de stress du réticulum augmentent significativement l’expression de MELOE-1. Cela pourrait refléter les conditions de stress dans l'environnement tumoral in vivo. En conclusion, les antigènes issus de la traduction IRES-dépendante de meloe sont les cibles thérapeutiques les plus pertinentes et notre hypothèse actuelle est que de tels antigènes IRES-dépendants existent probablement dans d'autres types de cellules cancéreuses à partir d'autres lncRNA.

  • Open Access

    Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors

    by Nils-Petter Rudqvist, Maud Charpentier, Claire Lhuillier, Erik Wennerberg, Sheila Spada, Caroline Sheridan, Xi Kathy Zhou, Tuo Zhang, Silvia C. Formenti, Jennifer S. Sims, et al.

    Radiation therapy (RT) increases tumor response to CTLA-4 inhibition (CTLA4i) in mice and in some patients, yet deep responses are rare. To identify rational combinations of immunotherapy to improve responses we use models of triple negative breast cancer highly resistant to immunotherapy in female mice. We find that CTLA4i promotes the expansion of CD4+ T helper cells, whereas RT enhances T cell clonality and enriches for CD8+ T cells with an exhausted phenotype. Combination therapy decreases regulatory CD4+ T cells and increases effector memory, early activation and precursor exhausted CD8+ T cells. A combined gene signature comprising these three CD8+ T cell clusters is associated with survival in patients. Here we show that targeting additional immune checkpoints expressed by intratumoral T cells, including PD1, is not effective, whereas CD40 agonist therapy recruits resistant tumors into responding to the combination of RT and CTLA4i, indicating the need to target different immune compartments.


  • Open Access

    Supplementary Figures from Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses

    by Karsten A. Pilones, Maud Charpentier, Elena Garcia-Martinez, Camille Daviaud, Jeffrey Kraynak, Joseph Aryankalayil, Silvia C. Formenti, Sandra Demaria

  • Open Access

    Data from Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses

    by Karsten A. Pilones, Maud Charpentier, Elena Garcia-Martinez, Camille Daviaud, Jeffrey Kraynak, Joseph Aryankalayil, Silvia C. Formenti, Sandra Demaria

    Focal radiotherapy can promote cross-presentation of tumor antigens to T cells, but by itself, it is insufficient to induce therapeutically effective T-cell responses. The common gamma-chain cytokine IL15 promotes and sustains the proliferation and effector function of CD8+ T cells but has limited activity against poorly immunogenic tumors that do not elicit significant spontaneous T-cell responses. Here, we show that radiotherapy and subcutaneous IL15 had complementary effects and induced CD8+ T-cell–mediated tumor regression and long-term protective memory responses in two mouse carcinoma models unresponsive to IL15 alone. Mechanistically, radiotherapy-induced IFN type I production and Batf3-dependent conventional dendritic cells type 1 (cDC1) were required for priming of tumor-specific CD8+ T cells and for the therapeutic effect of the combination. IL15 cooperated with radiotherapy to activate and recruit cDC1s to the tumor. IL15 alone and in complex with a hybrid molecule containing the IL15α receptor have been tested in early-phase clinical trials in patients with cancer and demonstrated good tolerability, especially when given subcutaneously. Expansion of natural killer (NK) cells and CD8+ T cells was noted, without clear clinical activity, suggesting further testing of IL15 as a component of a combinatorial treatment with other agents. Our results provide the rationale for testing combinations of IL15 with radiotherapy in the clinic.

  • Open Access

    Data from Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses

    by Karsten A. Pilones, Maud Charpentier, Elena Garcia-Martinez, Camille Daviaud, Jeffrey Kraynak, Joseph Aryankalayil, Silvia C. Formenti, Sandra Demaria

    Focal radiotherapy can promote cross-presentation of tumor antigens to T cells, but by itself, it is insufficient to induce therapeutically effective T-cell responses. The common gamma-chain cytokine IL15 promotes and sustains the proliferation and effector function of CD8+ T cells but has limited activity against poorly immunogenic tumors that do not elicit significant spontaneous T-cell responses. Here, we show that radiotherapy and subcutaneous IL15 had complementary effects and induced CD8+ T-cell–mediated tumor regression and long-term protective memory responses in two mouse carcinoma models unresponsive to IL15 alone. Mechanistically, radiotherapy-induced IFN type I production and Batf3-dependent conventional dendritic cells type 1 (cDC1) were required for priming of tumor-specific CD8+ T cells and for the therapeutic effect of the combination. IL15 cooperated with radiotherapy to activate and recruit cDC1s to the tumor. IL15 alone and in complex with a hybrid molecule containing the IL15α receptor have been tested in early-phase clinical trials in patients with cancer and demonstrated good tolerability, especially when given subcutaneously. Expansion of natural killer (NK) cells and CD8+ T cells was noted, without clear clinical activity, suggesting further testing of IL15 as a component of a combinatorial treatment with other agents. Our results provide the rationale for testing combinations of IL15 with radiotherapy in the clinic.

  • Open Access

    Supplementary Figures from Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses

    by Karsten A. Pilones, Maud Charpentier, Elena Garcia-Martinez, Camille Daviaud, Jeffrey Kraynak, Joseph Aryankalayil, Silvia C. Formenti, Sandra Demaria

  • Open Access

    Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors

    by Nils-Petter Rudqvist, Maud Charpentier, Claire Lhuillier, Erik Wennerberg, Sheila Spada, Caroline Sheridan, Xi Zhou, Tuo Zhang, Silvia Formenti, Jennifer Sims, et al.

    Radiation therapy (RT) increases tumor response to CTLA-4 inhibition (CTLA4i) in mice and in some patients, yet deep responses are rare. This raises the possibility that effector T cells are insufficiently activated by the combination. To address this question we use mouse models of triple negative breast cancer highly resistant to immunotherapy. We find that CTLA4i promotes the expansion of CD4+ T helper cells, whereas RT enhances T cell clonality and enriches for CD8+ T cells with an exhausted phenotype. Combination therapy decreases regulatory CD4+ T cells and increases CD8+ T cells with effector memory, early activation and precursor exhausted phenotype. A combined gene signature comprising these three CD8+ T cell clusters is associated with survival in triple negative breast cancer patients. Despite the expression of multiple immune checkpoints on intratumoral T cells, response to RT+CTLA4i is not increased by targeting additional checkpoints, including PD1. In contrast, agonistic CD40 therapy enhances responses in mice, indicating the need to target different immune compartments to increase responses to combinations of RT and CTLA4i.

  • Open Access

    hnRNP‐A1 binds to the IRES of MELOE‐1 antigen to promote MELOE‐1 translation in stressed melanoma cells

    by Maud Charpentier, Emilie Dupré, Agnès Fortun, Floriane Briand, Mike Maillasson, Emmanuelle Com, Charles Pineau, Nathalie Labarrière, Catherine Rabu, François Lang

    The major challenge in antigen‐specific immunotherapy of cancer is to select the most relevant tumor antigens to target. To this aim, understanding their mode of expression by tumor cells is critical. We previously identified a melanoma‐specific antigen, melanoma‐overexpressed antigen 1 (MELOE‐1)—coded for by a long noncoding RNA—whose internal ribosomal entry sequence (IRES)‐dependent translation is restricted to tumor cells. This restricted expression is associated with the presence of a broad‐specific T‐cell repertoire that is involved in tumor immunosurveillance in melanoma patients. In the present work, we explored the translation control of MELOE‐1 and provide evidence that heterogeneous nuclear ribonucleoprotein A1 (hnRNP‐A1) binds to the MELOE‐1 IRES and acts as an IRES trans‐activating factor (ITAF) to promote the translation of MELOE‐1 in melanoma cells. In addition, we showed that endoplasmic reticulum (ER) stress induced by thapsigargin, which promotes hnRNP‐A1 cytoplasmic translocation, enhances MELOE‐1 translation and recognition of melanoma cells by a MELOE‐1‐specific T‐cell clone. These findings suggest that pharmacological stimulation of stress pathways may enhance the efficacy of immunotherapies targeting stress‐induced tumor antigens such as MELOE‐1.


  • Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control

    by Claire Lhuillier, Nils-Petter Rudqvist, Takahiro Yamazaki, Tuo Zhang, Maud Charpentier, Lorenzo Galluzzi, Noah Dephoure, Cristina C. Clement, Laura Santambrogio, Xi Kathy Zhou, et al.

    Neoantigens generated by somatic nonsynonymous mutations are key targets of tumor-specific T cells, but only a small number of mutations predicted to be immunogenic are presented by MHC molecules on cancer cells. Vaccination studies in mice and patients have shown that the majority of neoepitopes that elicit T cell responses fail to induce significant antitumor activity, for incompletely understood reasons. We report that radiotherapy upregulates the expression of genes containing immunogenic mutations in a poorly immunogenic mouse model of triple-negative breast cancer. Vaccination with neoepitopes encoded by these genes elicited CD8+ and CD4+ T cells that, whereas ineffective in preventing tumor growth, improved the therapeutic efficacy of radiotherapy. Mechanistically, neoantigen-specific CD8+ T cells preferentially killed irradiated tumor cells. Neoantigen-specific CD4+ T cells were required for the therapeutic efficacy of vaccination and acted by producing Th1 cytokines, killing irradiated tumor cells, and promoting epitope spread. Such a cytotoxic activity relied on the ability of radiation to upregulate class II MHC molecules as well as the death receptors FAS/CD95 and DR5 on the surface of tumor cells. These results provide proof-of-principle evidence that radiotherapy works in concert with neoantigen vaccination to improve tumor control.


  • Open Access

    Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses

    by Karsten A. Pilones, Maud Charpentier, Elena Garcia-Martinez, Camille Daviaud, Jeffrey Kraynak, Joseph Aryankalayil, Silvia C. Formenti, Sandra Demaria

    Focal radiotherapy can promote cross-presentation of tumor antigens to T cells, but by itself, it is insufficient to induce therapeutically effective T-cell responses. The common gamma-chain cytokine IL15 promotes and sustains the proliferation and effector function of CD8+ T cells but has limited activity against poorly immunogenic tumors that do not elicit significant spontaneous T-cell responses. Here, we show that radiotherapy and subcutaneous IL15 had complementary effects and induced CD8+ T-cell–mediated tumor regression and long-term protective memory responses in two mouse carcinoma models unresponsive to IL15 alone. Mechanistically, radiotherapy-induced IFN type I production and Batf3-dependent conventional dendritic cells type 1 (cDC1) were required for priming of tumor-specific CD8+ T cells and for the therapeutic effect of the combination. IL15 cooperated with radiotherapy to activate and recruit cDC1s to the tumor. IL15 alone and in complex with a hybrid molecule containing the IL15α receptor have been tested in early-phase clinical trials in patients with cancer and demonstrated good tolerability, especially when given subcutaneously. Expansion of natural killer (NK) cells and CD8+ T cells was noted, without clear clinical activity, suggesting further testing of IL15 as a component of a combinatorial treatment with other agents. Our results provide the rationale for testing combinations of IL15 with radiotherapy in the clinic.